Elizabeth Yeu Lin Sells 390 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 390 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $26,130.00. Following the completion of the sale, the insider directly owned 23,308 shares of the company’s stock, valued at $1,561,636. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total value of $26,041.09.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total value of $26,032.50.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $64.51 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market cap of $2.75 billion, a PE ratio of -39.82 and a beta of 0.55. The business has a 50-day simple moving average of $69.12 and a two-hundred day simple moving average of $70.22. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on TARS. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Barclays initiated coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Tarsus Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after acquiring an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after acquiring an additional 1,394 shares during the period. Jane Street Group LLC lifted its holdings in Tarsus Pharmaceuticals by 105.8% in the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after acquiring an additional 190,000 shares during the period. Envestnet Asset Management Inc. boosted its position in Tarsus Pharmaceuticals by 15.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock worth $420,000 after purchasing an additional 1,418 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Tarsus Pharmaceuticals by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after purchasing an additional 68,986 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.